Oncology Venture awarded research grant for drug screening
With fresh funding of more than USD 1.5 million, Denmark-based biotech company Oncology Venture can accelerate screening of patients to take part in a clinical study of its multiple myeloma candidate - a study that could kick off later this year.
BY LOUISE WENDT JENSEN
The Norwegian Research Council has granted NOK 6 million to Danish-based Oncology Venture for the biotech company to screen patients for response to its immuno-oncology candidate APO010, which targets multiple myeloma – a cancer of the bone marrow.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish company moves listing to Sweden
For abonnenter
MPI agrees to cancer collaboration with German company
For abonnenter
